ReviewCells2021
Regulatory T Cell-Enhancing Therapies to Treat Atherosclerosis.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- CD8Immunity & ageing : I & A · 2026Article
- Reprogramming Atherosclerosis: Precision Drug Delivery, Nanomedicine, and Immune-Targeted Therapies for Cardiovascular Risk Reduction.Pharmaceutics · 2025Review
- Targeted drug delivery systems for atherosclerosis.Journal of nanobiotechnology · 2025Review
- Relationship Between Inflammatory Readings and the Degree of Coronary Atherosclerosis (Pilot Study).Journal of clinical medicine · 2024Article
- Nano Delivery System for Atherosclerosis.Journal of functional biomaterials · 2024Review
- Treg Immunomodulation Contributes to the Anti-atherosclerotic Effects of Huxin Formula in ApoEChinese journal of integrative medicine · 2024Article
- T-Cell Metabolic Reprogramming in Atherosclerosis.Biomedicines · 2024Review
- Regulatory T cells and macrophages in atherosclerosis: from mechanisms to clinical significance.Frontiers in immunology · 2024Review
- Identification of human exTNature immunology · 2023Article
- A novel interleukin-2-based fusion molecule, HCW9302, differentially promotes regulatory T cell expansion to treat atherosclerosis in mice.Frontiers in immunology · 2023Article
- How the immune system shapes atherosclerosis: roles of innate and adaptive immunity.Nature reviews. Immunology · 2022Review
- Vaccination against Atherosclerosis: Is It Real?International journal of molecular sciences · 2022Review
- Crosstalk between dendritic cells and T lymphocytes during atherogenesis: Focus on antigen presentation and break of tolerance.Frontiers in cardiovascular medicine · 2022Review
- Recent Advances on the Role and Therapeutic Potential of Regulatory T Cells in Atherosclerosis.Journal of clinical medicine · 2021Review
- Inflammation and Atherosclerosis.Cells · 2021Article
- Mechanistic Insight into PPARγ and Tregs in Atherosclerotic Immune Inflammation.Frontiers in pharmacology · 2021Review
- Immunotherapeutic Strategies in Cancer and Atherosclerosis-Two Sides of the Same Coin.Frontiers in cardiovascular medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Experimental studies have provided strong evidence that chronic inflammation triggered by the sub-endothelial accumulation of cholesterol-rich lipoproteins in arteries is essential in the initiation and progression of atherosclerosis. Recent clinical trials highlighting the efficacy of anti-inflammatory therapies in coronary patients have confirmed that this is also true in humans Monocytes/macrophages are central cells in the atherosclerotic process, but adaptive immunity, through B and T lymphocytes, as well as dendritic cells, also modulates the progression of the disease. Analysis of the role of different T cell subpopulations in murine models of atherosclerosis identified effector Th1 cells as proatherogenic, whereas regulatory T cells (Tregs) have been shown to protect against atherosclerosis. For these reasons, better understanding of how Tregs influence the atherosclerotic process is believed to provide novel Treg-targeted therapies to combat atherosclerosis. This review article summarizes current knowledge about the role of Tregs in atherosclerosis and discusses ways to enhance their function as novel immunomodulatory therapeutic approaches against cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.